Linagliptin(lin ah glip’ tin)
Tradjenta
PREGNANCY CATEGORY B
Drug Classes
Antidiabetic
Dipeptidyl peptidase-4 (DPP-4) inhibitor
Therapeutic Actions
Slows the inactivation of the incretin hormones by DPP-4, increasing these hormone levels and prolonging their activity. The incretin hormones stimulate insulin release in response to a meal and help regulate glucose homeostasis throughout the day. This action increases and prolongs insulin release and reduces hepatic glucose production to help achieve glycemic control.
Indications
-
As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
NEW INDICATION: • As an adjunct to insulin, diet, and exercise to achieve glycemic control in type 2 diabetics
Contraindications and Cautions
-
Contraindicated with history of serious hypersensitivity reactions to linagliptin.
-
Use cautiously with concurrent use of strong CYP3A inducers; pregnancy, lactation.
Available Forms
Tablets—5 mg
Dosages
Adults
5 mg PO once a day without regard to food.
Pediatric patients
Safety and efficacy not established.
Pharmacokinetics
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
